Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy

Journal of Steroid Biochemistry and Molecular Biology

Volumn 86, Issue 3-5, 2003, Pages 289-293

  Smith, Ian E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Letrozole; Tamoxifen

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; BACKACHE; BONE PAIN; BREAST CARCINOMA; BREAST SURGERY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; HOT FLUSH; HUMAN; LEUKORRHEA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; WEIGHT GAIN;

EID: 0242457696     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00369-8     Document Type: Conference Paper

References (36)

1. Ingle J.N., Ahmann D.L., Green S.J.et al. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am. J. Clin. Oncol. 5:1982;155-160.
2. Muss H.B., Wells H.B., Paschold E.H.et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis - a phase III trial of the Piedmont Oncology Association. J. Clin. Oncol. 6:1988;1098-1106.
3. Muss H.B., Case L.D., Atkins J.N.et al. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association Study. J. Clin. Oncol. 12:1994;1630-1638.
4. Paterson A.H.G., Hanson J., Pritchard K.I.et al. Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. Semin. Oncol. 17(6 (Suppl. 9)):1990;52-62.
5. Gill P.G., Gebski V., Snyder R.et al. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann. Oncol. 4(9):1993;741-744.
6. Castiglione-Gertsch M., Pampallona S., Varini M.et al. Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate? Ann. Oncol. 4(9):1993;735-740.
7. Ingle J.N., Ahmann D.L., Green S.J.et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N. Engl. J. Med. 304(1):1981;16-21.
8. Kellokumpu-Lehtinen P., Huovinen R., Johansson R. Hormonal treatment of advanced breast cancer: a randomized trial of tamoxifen versus nandrolone decanoate. Cancer. 60:1987;2376-2381.
9. Hayes D.F., Van Zyl J.A., Hacking A.et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J. Clin. Oncol. 13(10):1995;2556-2566.
10. Stenbygaard L.E., Herrstedt J., Thomsen J.F.et al. Toremifene and tamoxifen in advanced breast cancer: a double-blind cross-over trial. Breast Cancer Res. Treat. 25:1993;57-63.
11. Smith I.E., Harris A.L., Morgan M.et al. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomised cross-over trial. Br. Med. J. 283:1981;1432-1434.
12. Lipton A., Harvey H.A., Santen R.J.et al. A randomised trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer. 50(11):1982;2265-2268.
13. Gale K.E., Andersen J.W., Tormey D.C.et al. Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group phase III trial comparing aminoglutethimide to tamoxifen. Cancer. 73:1994;354-361.
14. Falkson C.I., Falkson H.C. A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. Ann. Oncol. 7:1996;465-469.
15. Thurlimann B., Beretta K., Bacchi M.et al. First-line fadrozole HCl (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann. Oncol. 7:1996;471-479.
16. Perez Carrion R., Alberola Candel V., Calabresi F.et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann. Oncol. 5(Suppl. 7):1994;S19-S24.
17. Mouridsen H., Gershanovich M., Sun Y.et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. 19(10):2001;2596-2606.
18. Robertson J.F.R., Willsher P.C., Cheung K.L.et al. Clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur. J. Cancer. 33:1997;1774-1779.
19. Howell A., Mackintosh J., Jones M.et al. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur. J. Cancer Clin. Oncol. 24:1988;1567-1572.
20. Robertson J.F.R., Howell A., Buzdar A.et al. Static disease on anastrozole provides similar benefits as objective response in patients with advanced breast cancer. Breast Cancer Res. Treat. 58:1999;157-162.
21. Mouridsen H., Sun Y., Gershanovich M.et al. Final survival analysis of the double-blind, randomized, multinational phase III trial of letrozole (Femara) compared to tamoxifen as first-line hormonal therapy for advanced breast cancer. Breast Cancer Res. Treat. 69(3):2001;211. (Abstract 219).
22. Robertson J.F., Ellis I.O., Elston C.W.et al. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur. J. Cancer. 28:1992;908-910.
23. J.C. Gazet, H.T. Ford, C.R. Coombes, et al., Prospective randomized trial of tamoxifen vs. surgery in elderly patients with breast cancer, Eur. J. Surg. Oncol. 20 (3) (1994) 207-214.
24. Mustacchi G., Milani S., Pluchinotta A., De Matteis A., Rubagotti A., Perrota A. Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer. The GRETA Trial Group for Research on Endocrine Therapy in the Elderly. Anti-Cancer Res. 14(5B):1994;2197-2200.
25. Bates T., Riley D.L., Houghton J.et al. Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. Br. J. Surg. 78(5):1991;591-594.
26. Kenny F.S., Robertson J.F.R., Ellis I.O., Elston C.W., Blamey R.W. Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast carcinoma. Breast. 7:1998;335-339.
27. Forrest A.P., Levack P.A., Chetty U.et al. A human tumour model. Lancet. 2(8511):1986;840-842.
28. Dixon J.M., Love C.D., Bellamy C.O.et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res. Treat. 66(3):2001;191-199.
29. Dixon J.M., Renshaw L., Bellamy C., Stuart M., Hoctin-Boes G., Miller W.R. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin. Cancer Res. 6(6):2000;2229-2235.
30. Miller W.R., Dixon J.M. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control. 9(Suppl.):2002;9-15.
31. J.M. Dixon, Neoadjuvant endocrine therapy, in: W.R. Miller, R.J. Santen (Eds.), Aromatase Inhibition and Breast Cancer, Marcel Dekker, New York, 2000, pp. 103-116.
32. Eiermann W., Paepke S., Apffelstaedt J.et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol. 12:2001;1527-1532.
33. Ellis M.J., Coop A., Singh B.et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin Oncol. 19(18):2001;3808-3816.
34. Nabholtz J.M., Buzdar A., Pollak M.et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast carcinoma in postmenopausal women: results of a North American multicenter randomized trial. J. Clin. Oncol. 18(22):2000;3758-3767.
35. Bonneterre J., Thurlimann B., Robertson J.F.R.et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J. Clin. Oncol. 18(22):2000;3748-3757.
36. ATAC Trialists Group, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial, Lancet 359 (9324) (2002) 2131-2139.